Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Kowa Company and Daiichi Sankyo have decided to terminate the joint marketing partnership for sales of Livalo and Olmetec in Japan, effective 30 June 2013.
Subscribe to our email newsletter
Livalo, developed by Kowa, is a cholesterol-lowering agent and Olmetec, developed by Daiichi, is an antihypertensive agent.
Both the companies have been jointly marketing the drugs in the region since their launch but subsequent to the review of sales strategy and discussions a decision to close the agreement is taken.
From 1 July 2013, Kowa will solely conduct the promotion and marketing activities of Livalo tablets and Daiichi Sankyo will solely conduct the Olmetec promotion and marketing activites.